These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32373232)

  • 1. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
    Boot A; Jiang N; Rozen SG
    Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 4. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
    Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
    Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs.
    Yang HY; Yang CC; Wu CY; Wang LJ; Lu KL
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium.
    Chen CH; Grollman AP; Huang CY; Shun CT; Sidorenko VS; Hashimoto K; Moriya M; Turesky RJ; Yun BH; Tsai K; Wu S; Chuang PY; Tang CH; Yang WH; Tzai TS; Tsai YS; Dickman KG; Pu YS
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):317-325. PubMed ID: 33277322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macroscopic somatic clonal expansion in morphologically normal human urothelium.
    Li R; Du Y; Chen Z; Xu D; Lin T; Jin S; Wang G; Liu Z; Lu M; Chen X; Xu T; Bai F
    Science; 2020 Oct; 370(6512):82-89. PubMed ID: 33004515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
    Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
    Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
    Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
    Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
    Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
    Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J
    Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy.
    Kanaan N; Hassoun Z; Raggi C; Jadoul M; Mourad M; De Meyer M; Aydin S; Schmeiser HH; Cosyns JP; Goffin E
    Transplantation; 2016 Feb; 100(2):416-21. PubMed ID: 26457602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aristolochic acid-associated urothelial cancer in Taiwan.
    Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
    Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
    Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X
    BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.
    Ng AWT; Poon SL; Huang MN; Lim JQ; Boot A; Yu W; Suzuki Y; Thangaraju S; Ng CCY; Tan P; Pang ST; Huang HY; Yu MC; Lee PH; Hsieh SY; Chang AY; Teh BT; Rozen SG
    Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
    Aydin S; Ambroise J; Cosyns JP; Gala JL
    Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.
    Odell AF; Odell LR; Askham JM; Alogheli H; Ponnambalam S; Hollstein M
    J Biol Chem; 2013 Jun; 288(23):16704-16714. PubMed ID: 23612969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.